A randomised, double-blind, placebo-controlled phase II trial to evaluate the safety and efficacy of the anti-CCL2 antibody has been performed for patients with IPF, which emphasises the importance of the inhibition of this axis. The gene discussed is CCL2; the disease is idiopathic pulmonary fibrosis.